GlobeNewswire: MyoKardia, Inc. Contains the last 10 of 156 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T09:11:51ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/11/15/2126910/0/en/MyoKardia-Presents-Cardiac-Imaging-Data-from-30-Week-EXPLORER-HCM-Study-of-Mavacamten.html?f=22&fvtc=4&fvtv=27610MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten2020-11-15T21:30:00Z<![CDATA[EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation]]>https://www.globenewswire.com/news-release/2020/11/13/2126597/0/en/MyoKardia-Presents-Mavacamten-Clinical-and-Non-Clinical-Data-at-the-American-Heart-Association-s-Scientific-Sessions-2020.html?f=22&fvtc=4&fvtv=27610MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 20202020-11-13T15:00:00Z<![CDATA[ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients]]>https://www.globenewswire.com/news-release/2020/11/11/2124742/0/en/MyoKardia-Collaborates-with-the-American-College-of-Cardiology-and-PINNACLE-Veradigm-to-Launch-Patient-Registry-of-Hypertrophic-Cardiomyopathy.html?f=22&fvtc=4&fvtv=27610MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy2020-11-11T13:30:00Z<![CDATA[Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy]]>https://www.globenewswire.com/news-release/2020/11/05/2121564/0/en/MyoKardia-Reports-Third-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=27610MyoKardia Reports Third Quarter 2020 Financial Results2020-11-05T21:13:58Z<![CDATA[Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020]]>https://www.globenewswire.com/news-release/2020/11/04/2120111/0/en/MyoKardia-Announces-Awardees-of-the-Second-Annual-MyoSeeds-Research-Grants-Program.html?f=22&fvtc=4&fvtv=27610MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program2020-11-04T13:30:00Z<![CDATA[BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded to help advance MyoKardia’s mission to promote understanding and treatment of the underlying drivers of serious cardiovascular diseases.]]>https://www.globenewswire.com/news-release/2020/11/02/2118470/0/en/MyoKardia-Announces-Multiple-Abstracts-Selected-for-Presentation-at-the-Upcoming-American-Heart-Association-s-Annual-Scientific-Sessions-2020.html?f=22&fvtc=4&fvtv=27610MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 20202020-11-02T13:30:00Z<![CDATA[EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation]]>https://www.globenewswire.com/news-release/2020/09/09/2090844/0/en/MyoKardia-Doses-First-Patient-in-Phase-2-Clinical-Trial-of-Danicamtiv-in-Genetic-Dilated-Cardiomyopathy.html?f=22&fvtc=4&fvtv=27610MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy2020-09-09T12:00:00Z<![CDATA[BRISBANE, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere. Danicamtiv is MyoKardia’s most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.]]>https://www.globenewswire.com/news-release/2020/09/02/2087663/0/en/MyoKardia-to-Participate-in-September-Investor-Conferences.html?f=22&fvtc=4&fvtv=27610MyoKardia to Participate in September Investor Conferences2020-09-02T12:00:00Z<![CDATA[BRISBANE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2020/08/29/2085766/0/en/MyoKardia-Presents-Results-from-Phase-3-EXPLORER-HCM-Clinical-Trial-of-Mavacamten-for-the-Treatment-of-Obstructive-Hypertrophic-Cardiomyopathy.html?f=22&fvtc=4&fvtv=27610MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy2020-08-29T13:30:00Z<![CDATA[EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet]]>https://www.globenewswire.com/news-release/2020/08/11/2076300/0/en/MyoKardia-and-LianBio-Form-Strategic-Partnership-to-Develop-and-Commercialize-Mavacamten-Together-in-Greater-China.html?f=22&fvtc=4&fvtv=27610MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China2020-08-11T11:35:00Z<![CDATA[Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM]]>